Pharmacologic therapy for primary restless legs syndrome: A Systematic review and meta-analysis

JAMA Internal Medicine

Volumn 173, Issue 7, 2013, Pages 496-505

  Wilt, Timothy J ^a,b,c   MacDonald, Roderick ^a   Ouellette, Jeannine ^a,c   Khawaja, Imran S ^a,b   Rutks, Indulis ^a   Butler, Mary ^a,c   Fink, Howard A ^a,b,c,d  

^a VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; GABAPENTIN ENACARBIL; PLACEBO; PRAMIPEXOLE; PREGABALIN; ROPINIROLE; ROTIGOTINE;

COMPARATIVE EFFECTIVENESS; DATA BASE; DATA EXTRACTION; DATA SYNTHESIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; NAUSEA AND VOMITING; PRIORITY JOURNAL; QUALITY CONTROL; RATING SCALE; RESTLESS LEGS SYNDROME; REVIEW; SOMNOLENCE; SYSTEMATIC REVIEW;

DOPAMINE AGONISTS; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESTLESS LEGS SYNDROME;

EID: 84876052957     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2013.3733     Document Type: Review

References (47)

1. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J; Restless Legs Syndrome Diagnosis and Epidemiology workshop at the National Institutes of Health; International Restless Legs Syndrome Study Group. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology: a report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4(2):101-119.
2. Leschziner G, Gringras P. Restless legs syndrome. BMJ. 2012;344:e3056.
3. Walters AS; The International Restless Legs Syndrome Study Group. Toward a better definition of the restless legs syndrome. Mov Disord. 1995;10(5):634-642.
4. Trenkwalder C, Paulus W. Restless legs syndrome: pathophysiology, clinical presentation and management. Nat Rev Neurol. 2010;6(6):337-346.
5. García-Borreguero D, Egatz R, Winkelmann J, Berger K. Epidemiology of restless legs syndrome: the current status. Sleep Med Rev. 2006;10(3):153-167.
6. Wilt TJ, MacDonald R, Ouellette J, et al. Treatments for restless legs syndrome. Rockville, MD: Agency for Healthcare Research and Quality; 2012. AHRQ Publication No. 12 (13)-EHC147-EF. http://www.effectivehealthcare.ahrq.gov/ search-for-guides-reviews-and-reports/?pageaction =displayproduct&productID= 1327&ECem =121127. Accessed December 2012.
7. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011. http://www.cochrane-handbook.org. Accessed January 2012.
8. Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions-agency for healthcare research and quality and the effective health-care program. J Clin Epidemiol. 2010;63(5):513-523.
9. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634.
10. Ferini-Strambi L, Aarskog D, Partinen M, et al. Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial. Sleep Med. 2008;9(8):874-881.
11. Högl B, Garcia-Borreguero D, Trenkwalder C, et al. Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome. Sleep Med. 2011;12(4):351-360.
12. Montagna P, Hornyak M, Ulfberg J, et al. Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood. Sleep Med. 2011;12(1):34-40.
13. Oertel WH, Stiasny-Kolster K, Bergtholdt B, et al; Pramipexole RLS Study Group. Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study). Mov Disord. 2007;22(2):213-219.
14. Winkelman JW, Sethi KD, Kushida CA, et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology. 2006;67(6):1034-1039.
15. Adler CH, Hauser RA, Sethi K, et al. Ropinirole for restless legs syndrome: a placebo-controlled crossover trial. Neurology. 2004;62(8):1405-1407.
16. Benes H, Mattern W, Peglau I, et al. Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomized, placebo-controlled study. J Neurol. 2011;258(6):1046-1054.
17. Bogan RK, Fry JM, Schmidt MH, Carson SW, Ritchie SY; TREAT RLS US Study Group. Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc. 2006;81(1):17-27.
18. Kushida CA, Geyer J, Tolson JM, Asgharian A. Patient-andphysician- ratedmeasuresdemonstrate theeffectivenessofropiniroleinthetreatmentofrestless legs syndrome. Clin Neuropharmacol. 2008;31(5):281-286.
19. Montplaisir J, Karrasch J, Haan J, Volc D. Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial. Mov Disord. 2006;21(10):1627-1635.
20. Trenkwalder C, Garcia-Borreguero D, Montagna P, et al; Therapy with Ropiunirole; Efficacy and Tolerability in RLS 1 Study Group. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry. 2004;75(1):92-97.
21. Walters AS, Ondo WG, Dreykluft T, Grunstein R, Lee D, Sethi K; TREAT RLS 2 (Therapy with Ropinirole: Efficacy And Tolerability in RLS 2) Study Group. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord. 2004;19(12):1414-1423.
22. Hening WA, Allen RP, Ondo WG, et al; SP792 Study Group. Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebocontrolled trial in the United States. Mov Disord. 2010;25(11):1675-1683.
23. Oertel WH, Benes H, Garcia-Borreguero D, et al. Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study. Sleep Med. 2010;11(9):848-856.
24. Trenkwalder C, Benes H, Poewe W, et al; SP790 Study Group. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2008;7(7):595-604.
25. Oertel WH, Benes H, Garcia-Borreguero D, et al; Rotigotine SP 709 Study Group. Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebocontrolled, six-week dose-finding trial in Europe. Sleep Med. 2008;9(3):228-239.
26. Oertel WH, Benes H, Bodenschatz R, et al. Efficacy of cabergoline in restless legs syndrome: a placebocontrolled study with polysomnography (CATOR). Neurology. 2006;67(6):1040-1046.
27. Stiasny-Kolster K, Benes H, Peglau I, et al. Effective cabergoline treatment in idiopathic restless legs syndrome. Neurology. 2004;63(12):2272- 2279.
28. Bassetti CL, Bornatico F, Fuhr P, Schwander J, Kallweit U, Mathis J; Swiss RLS study group. Pramipexole versus dual release levodopa in restless legs syndrome: a double blind, randomised, cross-over trial. Swiss Med Wkly. 2011;141:w13274.
29. Trenkwalder C, Benes H, Grote L, et al; CALDIR Study Group. Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multicenter, randomized, active controlled trial. Mov Disord. 2007;22(5):696-703.
30. Lee DO, Ziman RB, Perkins AT, Poceta JS, Walters AS, Barrett RW; XP053 Study Group. A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. J Clin Sleep Med. 2011;7(3):282-292.
31. Bogan RK, Bornemann MAC, Kushida CA, Trân PV, Barrett RW; XP060 Study Group. Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study. Mayo Clin Proc. 2010;85(6):512-521.
32. Kushida CA, Becker PM, Ellenbogen AL, Canafax DM, Barrett RW; XP052 Study Group. Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Neurology. 2009;72(5):439-446.
33. Winkelman JW, Bogan RK, Schmidt MH, Hudson JD, De Rossett SE, Hill-Zabala CE. Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome. Mov Disord. 2011;26(11):2065-2072.
34. Allen R, Chen C, Soaita A, et al. A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. Sleep Med. 2010;11(6):512-519.
35. Garcia-Borreguero D, Larrosa O, Williams AM, et al. Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study. Neurology. 2010;74(23):1897-1904.
36. Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology. 2002;59(10):1573-1579.
37. Allen RP, Adler CH, Du W, Butcher A, Bregman DB, Earley CJ. Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial. Sleep Med. 2011;12(9):906-913.
38. Bayard M, Bailey B, Acharya D, et al. Bupropion and restless legs syndrome: a randomized controlled trial. J Am Board Fam Med. 2011;24(4):422-428.
39. Aurora RN, Kristo DA, Bista SR, et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults-an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. Sleep. 2012;35(8):1039-1062.
40. Garcia-Borreguero D, Ferini-Strambi L, Kohnen R, et al. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. Eur J Neurol. 2012;19(11):1385-1396.
41. Silber MH, Ehrenberg BL, Allen RP, et al; Medical Advisory Board of the Restless Legs Syndrome Foundation. An algorithm for the management of restless legs syndrome. Mayo Clin Proc. 2004;79(7):916-922.
42. Williams G. Neurology Reviews website. From the 64th Annual Meeting of the American Academy of Neurology-Pregabalin Versus Pramipexole for Restless Legs Syndrome. April 26, 2012. http://www.neurologyreviews.com/Article.aspx? ArticleId=dkzFZBk66Xk=&FullText=1. Accessed August 2012.
43. Lettieri CJ, Eliasson AH. Pneumatic compression devices are an effective therapy for restless legs syndrome: a prospective, randomized, doubleblinded, sham-controlled trial. Chest. 2009;135(1):74-80.
44. Mitchell UH, Myrer JW, Johnson AW, Hilton SC. Restless legs syndrome and near-infrared light: an alternative treatment option. Physiother Theory Pract. 2011;27(5):345-351.
45. Aukerman MM, Aukerman D, Bayard M, Tudiver F, Thorp L, Bailey B. Exercise and restless legs syndrome: a randomized controlled trial. J Am Board Fam Med. 2006;19(5):487-493.
46. Cuellar NG, Ratcliffe SJ. Does valerian improve sleepiness and symptom severity in people with restless legs syndrome? Altern Ther Health Med. 2009;15(2):22-28.
47. Woloshin S, Schwartz LM. Giving legs to restless legs: a case study of how the media helps make people sick. PLoS Med. 2006;3(4):e170.